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Background Growing evidence suggests that atopic dermatitis (AD) is associated
with an increased risk of depressive disorders and anxiety. However, existing
studies were observational and may have uncovered correlations but could not
easily disentangle noncausal or reverse-causal associations because these associa-
tions could be confounded and may not reflect true causal relationships.
Objectives To examine, in a two-sample Mendelian randomization study, the
potential effect of AD on the risk of depressive disorders and anxiety.
Methods Genetic instruments from the largest available genome-wide association
study (GWAS) for AD (10 788 cases and 30 047 controls) were used to investi-
gate the relationship to broad depression (170 756 cases and 329 443 controls),
major depressive disorder (MDD; 30 603 cases and 143 916 controls) and anxi-
ety (5580 cases and 11 730 controls). A set of complementary approaches were
carried out to assess horizontal pleiotropy and related potential caveats occurring
in MR studies.
Results We observed no causal impact of AD on the risk of depressive disorders
and anxiety, with close-to-zero effect estimates. The inverse weighted method
revealed no associations of AD on broad depression [odds ratio (OR) 1014;
P = 0431], probable MDD (OR 1002; P = 0568), International Classification
of Diseases, Ninth/Tenth Revision-based MDD (OR 1001; P = 0466) or anxiety
(OR 1097; P = 0180).
Conclusions This MR study does not support a causal effect of AD on depression
and anxiety.
What is already known about this topic?
• There is growing evidence that atopic dermatitis (AD) is related to depressive dis-
orders and anxiety.
• Observational studies are prone to reverse causation and confounding, distorting
true relationships.
• Observational study results are inconclusive regarding the effect of AD on depres-
sion and anxiety.
What does this study add?
• Using Mendelian randomization as an alternative approach to investigate causality,
we did not find a causal relationship between AD and depressive disorders or anxiety.
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Depression was found to be the third leading cause of nonfatal
health loss in the 2017 Global Burden of Disease Study,1
affecting > 300 million people worldwide.2 The World Health
Organization ranks depression as the single largest contributor
to global disability and as a major contributor to death by sui-
cide, with about 800 000 fatalities per annum. Atopic der-
matitis (AD) is the most common chronic inflammatory skin
disorder. It has a complex pathophysiology encompassing a
genetic predisposition and environmental triggers,3 and affects
15–20% of children and 5–10% of adults.4
Emerging evidence has suggested that AD is associated with
depression and anxiety,5 reducing the quality of life of those
affected.6 In a matched case–control study exploiting routinely
collected data from the UK Clinical Practice Research Datalink,
the results showed a significantly increased risk of incident
depression and anxiety in patients with AD.7 These potential
associations between AD and depression and anxiety have
been further substantiated by systematic reviews and meta-
analyses.8,9
However, previous studies were based on observational epi-
demiological designs, which are prone to reverse causation
and unmeasured confounding.10 Mendelian randomization
(MR) provides an alternative approach to investigating causal-
ity by using genetic variants as instrumental variables and
thereby accounting for observational study bias.11,12 We pre-
sent a MR study on the association of AD and the risks of
depression and anxiety.
Materials and methods
We carried out a two-sample MR analysis based on summary
statistics, where the instrument–exposure and instrument–out-
come associations were estimated in independent samples. We
retrieved associations of single-nucleotide polymorphisms
(SNPs) with AD from a subset of the largest genome-wide
association study (GWAS) of European descent.13 SNP–out-
come associations were derived from genetic association data
on depression and anxiety.14–16 Additionally, we carried out
positve and negative control outcome analyses to assess the
potential biasing influences from horizontal pleiotropy and
selection bias,17–19 and tested for reverse causation bias.17,20 A
positive control outcome is an outcome for which it is already
well established that the exposure is causal. A negative control
is an outcome lacking a causal link with the exposure. Reverse
causation is present if the outcome influences the exposure
leading to distorted SNP–outcome associations and thus mis-
leading inference.
Selection of genetic instrumental variables for atopic
dermatitis
For AD genome-wide summary statistics from a GWAS of 10
788 patients with AD and 30 047 controls from 20 studies of
European descent were publicly available, excluding the
23andMe study.13 All analyses were based on this dataset.
These samples had been genotyped, imputed to 1000
Genomes Project Phase 1 (release March 2012), harmonized
and variants with minor allele frequencies > 1% were analysed
across studies. Summary statistics were reported for variants
with high imputation quality (r2 > 03 for MACH and proper
info > 04 for IMPUTE). In order to exclude variants with
spurious linkage disequilibrium, we used a clumping algo-
rithm (r2 threshold = 0001; window size = 10 mB)
(Table S1; see Supporting Information).
For instrument selection we chose two strategies. Firstly,
we used genetic instruments on a lower significance threshold
(P < 5 9 10–4) in order to increase the explained phenotypic
variance and thus the statistical power. Secondly, we selected
the 25 established genome-wide significant (P < 5 9 10–8)
sentinel SNPs reported in the largest GWAS of AD conducted
in a European discovery cohort of 18 900 cases and 84 166
controls (the sample above plus the 23andMe study) and
replicated in independent samples comprising 30 588 cases
and 226 537 controls of European descent,13 totalling 49 488
cases of AD and 310 703 controls (Table S2; see Supporting
Information). This approach can be considered a three-sample
MR analysis because genetic instruments were obtained from
the complete genetic study on AD (including discovery and
replication),13,17 while available exposure summary statistics
were derived from a subsample representing 113% of the
total sample size.
Genome-wide association study summary statistics for
depression and anxiety
SNP–outcome associations were retrieved from the most
recent and largest GWAS meta-analyses on broad depression,
excluding 23andMe, from 33 studies of the Psychatric Geno-
mics Consortium and the UK Biobank,14,15 totalling 170 756
cases and 329 443 controls. GWAS summary statistics for
probable and International Classification of Diseases, Ninth/
Tenth Revision (ICD-9/10)-coded major depressive disorder
(MDD) were obtained from the UK Biobank with 30 603
cases and 143 916 controls, and 8276 cases and 209 308 con-
trols, respectively. Broad depression was defined as self-
reported past help-seeking for problems with nerves, anxiety,
tension or depression, while probable MDD was acertained by
self-reported depressive symptoms with associated impair-
ment, and ICD-9/10-coded MDD was based on hospital
admission records. GWAS summary statistics for anxiety were
derived from the Anxiety NeuroGenetics Study (ANGST) Con-
sortium,16 comprising seven independent studies totalling
5580 patients with diagnosed anxiety disorder and 11 730
controls (Table S2).
Genome-wide association study summary statistics for
negative and positive control outcomes
A systematic review reported high asthma risk in young chil-
dren with AD;21 thus, we used asthma as a positive control
outcome. GWAS summary statistics for asthma were obtained
from the most recent GWAS meta-analysis.22 Summary
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statistics for the negative control outcome body height were
retrieved from the GIANT consortium (Table S2).23
Statistical analyses
Primary analysis
A priori statistical power was calculated according to Brion
et al.24 Summary statistics results were harmonized to ensure
effect size alignment and to prohibit strand mismatch. Wald
ratios were obtained by dividing the log odds ratio (OR) from
the SNP–outcome associations by the log OR of the corre-
sponding SNP–AD association, standard errors were calculated
using the delta method. Wald ratios were combined using the
multiplicative random effects inverse-variance weighted (IVW)
model for weak instruments, as well as for established AD risk
SNPs retrieved from an external sample.17 To adjust for multi-
ple testing, we applied the false-discovery rate and present
q values.25
Heterogeneity analysis and test for directional pleiotropy
Valid estimation of a causal effect using MR requires that all
instruments are independent of the outcome conditional on
the exposure and confounders.18 Violations of this assumption
through horizontal pleiotropy, whereby the instruments exert
an effect on the outcome independent of the exposure, can
introduce bias. To address the issue of pleiotropy, we exam-
ined the heterogeneity of ratio estimators, based on Cochran’s
Q, the I2 statistic, and the MR Egger intercept.18 In the case of
balanced pleiotropy (i.e. pleiotropic effects are independent of
the magnitude of the SNP–exposure associations; and if the
mean pleiotropic effect is zero), the effect can be reliably esti-
mated by the multiplicative random effects IVW method.17,18
Analyses using pleiotropy-robust methods
If the mean pleiotropic effect is nonzero, robust meta-analytic
methods are indicated.18 Thus, for sensitivity analyses, we car-
ried out a suite of pleiotropic-robust methods (weighted med-
ian; robust-adjusted profile score; radial regression MR; and
MR pleiotropy residual sum and outlier),26 applied leave-one-
out analysis to assess whether the IVW estimate was driven by
a single SNP, and performed positive and negative control
outcome analyses. Complementary MR analysis was carried
out using the causal analysis using summary effect estimates
(CAUSE) approach.27 By incorporating all genetic variants,
which increases statistical power, CAUSE assesses whether
GWAS summary statistics for the exposure and outcome are
consistent with a causal model, where the majority of variants
affect the outcome through the exposure, or with a shared
model, where the majority of variants affect an unobserved
heritable confounder acting on both exposure and outcome.
An integrated formal analysis tests the null hypothesis that
there is no difference in model fit between the sharing and
causal model. For this Bayesian approach, which estimates the
parameters c, the causal effect estimate, g, the effect of the
unobserved confounders on the outcome and q, the propor-
tion of variants acting via the confounders by a posterior dis-
tribution, parameter priors were set to default, as described
elsewhere.27 CAUSE has been demonstrated to make fewer
false detection of causal relationship in the presence of pleio-
tropy than other established methods.
Three-sample Mendelian randomization
In a two-sample MR study, weak instrument bias may mitigate
the estimated causal effect towards null. To overcome this
problem, three-sample MR studies have been proposed for
which genetic instruments are selected by one dataset,
whereas exposure outcome association by MR analysis is
carried out using two different datasets.17
Test for reverse causation, and negative and positive
control outcome
Further approaches to sensitivity analysis and assessment of
the robustness of the MR analysis are to test for reverse causa-
tion, and negative and positive control outcome.17 Reverse
causation (i.e. the outcome influencing the exposure) can be
tested using genetic instruments associated with the outcome
and carrying out MR analysis on the exposure. A positive con-
trol outcome is an outcome for which the causal exposure
outcome association is already established. A negative control
outcome is an outcome for which a causal link to the out-
come is lacking.
All analyses were performed using the packages metafor
(2.4.0), MendelianRandomization (0.4.2), TwoSampleMR
(0.5.5), MRPRESSO (1.0) and cause (1.2.0) in R, version
4.0.2. Reporting follows the STROBE-MR (Strengthening the




In total, 470 SNPs as weak genetic instruments (P < 5 9 10–4)
for AD explained 187% of the phenotypic variance. With a
type I error rate of 5%, there was ≥ 95% power to detect a
causal association of an OR > 110 with broad depression,
probable MDD and ICD-9/10-based MDD. We detected an
expected OR > 115 for anxiety with a power of > 96%
(Table S1). With regard to reverse causation, the explained
phenotypic variance of the 647 and 342 genetic instruments
for broad depression and anxiety is 25% and 297%, respec-
tively. We had ≥ 80% power to detect an expected OR of >
122 for depression and > 106 for anxiety on AD. Applying
standard IVW MR analysis, we found no evidence for effects
of genetically instrumented AD on broad depression [OR
0995, 95% confidence interval (CI) 099–100; P = 0068,
q = 0356)], probable MDD (OR 0999, 95% CI 0998–
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1001; P = 0413, q = 0596), ICD-9/10-based MDD (OR
100, 95% CI 0999–1000; P = 0345, q = 0596) or anxiety
(OR 1011, 95% CI 0962–1063; P = 0668, q = 0668)
(Table 1, Figure 1).
Heterogeneity analysis and test for directional pleiotropy
The strength of all 470 SNPs as genetic instruments measured
by the F statistics was greater than the common threshold of 10
(range 1213–11719). Substantial heterogeneity between Wald
ratios in the IVW estimate was observed only for broad depres-
sion, but low hetereogeneity was seen for all other outcomes
(Table S3; see Supporting Information). For all considered out-
comes, the intercept test from the MR Egger regression was not
statistically significant and did not indicate directionaly pleio-
tropy (Table S3), although the test might have been underpow-
ered.18 When more robust models towards directional
pleiotropy were employed, we observed strikingly similar esti-
mates of ORs close to 1 (0599 ≤ q ≤ 0780; Table 1). In addi-
tion, leave-one-out analyses showed no single SNP driving the
results (Table S4; see Supporting Information).
Analysis using pleiotropy-robust methods
Robust methods also indicated no relation of AD to depres-
sion, probable and ICD-9/10-based MDD or anxiety
(0246 ≤ q ≤ 0668; Table 1). The null associations were
futher supported by the CAUSE analysis, which did not indi-
cate that a causal model better fits the data than a shared
model for depression [OR 101, 95% credible interval (Cre-
dIn) 100–103; P = 0431], probable MDD (OR 100, 95%
CredIn 100–101; P = 0763), ICD-9/10-based MDD (OR
100, 95% CredIn 100–100; P = 0983) or anxiety (OR
102, 95% CredIn 0914–113; P = 0987).
Three-sample Mendelian randomization
To further corroborate the null findings, we adopted an
approach related to three-sample MR to select instruments
from the complete genetic study on AD (discovery and repli-
cation)13 and carry the established instruments explaining
15% of the phenotypic variance forward to the subset with
available summary statistics representing 113% of the com-
plete study (Table S5; see Supporting Information). Again, we
observed no association of genetic instrumented AD with
broad depression and anxiety (Figure 1, Table 1).
Test for reverse causation, and negative and positive
control outcome
For further sensitivity analyses, we calculated reverse causation
and carried out positive and negative control outcome analy-
ses. Neither reverse causation nor negative control outcome
revealed a significant effect of any mental outcome with AD
(Tables S6 and S7; see Supporting Information). However, an
observed association with the positve control outcome of
asthma showed a well-known strong causal association, con-
firming our analyses (Table S7).
Table 1 Mendelian randomization (MR) estimates for the relationship between genetically instrumented atopic dermatitis and broad depression,
probable and International Classification of Disease, Ninth/Tenth Revision (ICD-9/10)-based major depressive disorder (MDD), as well as anxiety
Outcome Method
Weak IVs (P < 5 9 10–4) Established AD loci (P < 5 9 10–9)13
OR 95% CI P-value q-value OR 95% CI P-value q-value
Broad depression IVW 0995 099–100 0068 0356 1014 0980–1048 0431 0676
Weighted median 0994 0987–1001 0105 0356 1018 0990–1047 0206 0676
Robust-adjusted profile score 0993 0988–0999 0012 0421 1018 0988–1048 0244 0599
IVW radial 0995 0991–100 0071 0246 1014 0980–1048 0430 0610
MR PRESSO 0996 0991–100 0070 0356 1019 0991–1048 0199 0599
Probable MDD IVW 0999 0998–1001 0413 0596 1002 0996–1008 0568 0676
Weighted median 0999 0997–1001 0516 0596 1001 0992–1010 0780 0676
Robust-adjusted profile score 0999 0998–1001 0226 0645 1002 0996–1009 0475 0780
IVW radial 0999 0998–1001 0413 0596 1002 0996–1008 0568 0676
MR PRESSO 0999 0998–1001 0413 0596 1002 0996–1008 0574 0676
ICD-9/10-based MDD IVW 1000 0999–1000 0345 0596 1001 0998–1004 0466 0676
Weighted median 1000 0999–1001 0580 0596 1001 0997–1005 0759 0676
Robust-adjusted profile score 1000 0999–1000 0255 0668 1002 0999–1005 0210 0780
IVW radial 1000 0999–1000 0346 0596 1001 0998–1004 0466 0599
MR PRESSO 1000 0999–1000 0345 0596 1001 0998–1004 0474 0676
Anxiety IVW 1011 0962–1063 0668 0668 1097 0958–1257 0180 0599
Weighted median 1030 0954–1113 0447 0668 1040 0861–1255 0685 0599
Robust-adjusted profile score 1022 0968–1079 0438 0596 1102 0953–1275 0191 0761
IVW radial 1011 0963–1062 0662 0596 1097 0976–1234 0121 0599
MR PRESSO 1011 0963–1062 0663 0668 1097 0976–1234 0135 0599
IVW, inverse-variance weighted; MR PRESSO, MR pleiotropy residual sum and outlier.
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Discussion
To the best of our knowledge, the current study represents the
first MR analysis of genetically determined AD in relation to
depressive disorders and anxiety. Using genetic instruments from
the largest available AD GWAS summary statistics of 10 788
cases and 30 047 controls, as well as from the largest depression
GWAS of 170 756 cases and 329 443 controls, we found no
evidence for a role of AD in the risk of depressive disorders and
anxiety. This finding does not support observational research,
where AD has been associated with an increased incidence of
depression and anxiety.7 In a systematic review and meta-
analysis including 18 studies on adults (91 324 patients with
AD and 6 046 825 reference individuals) an association between
AD and depression was shown (pooled OR 219, 95% CI 187–
257).8 In the same study, a meta-analysis on the relationship
between AD and anxiety based on 13 studies (38 225 adults
with AD and 4 523 540 reference individuals) also found a
positve association (pooled OR 219, 95% CI 175–273). A fur-
ther sytematic review and meta-analysis including observational
studies confirmed the strong association between AD and higher
depression scale scores.29 Our analysis does not support a causal
relationship between AD and depression. It is possible that the
previously observed positive association between AD and depres-
sion or anxiety is coincidental or is confounded by an unknown
factor and not directly caused by AD, for example symptoms
associated with AD such as chronic itch or treatment burden/
need. Furthermore, a causal link between AD and psychiatric
diseases cannot be determined in observational studies because
AD often occurs in combination with other diseases (e.g.
asthma),30,31 and thus it is possible that these comorbidities
contribute to the positive association between AD and depression
and anxiety. Finally, the associations between AD and psychiatric
disorders reported from cross-sectional studies and clinical stud-
ies were largely confined to severe AD with high burden,8,29
whereas the population of cases in the GWAS datsets used for
this analysis probably reflects a wider spectrum of severity. Thus,
although unlikely, we cannot completely rule out
nonoverlapping sets of risk factors, extreme multiformity or
even causal effects in severe AD strata.32
Two-sample MR enabled the use of the largest GWAS of
depression, MDD and anxiety to date. To achieve sufficient
statistical power to detect small effects of AD on risk depres-
sion, MDD and anxiety, we adopted a weak correlated instru-
ment approach.17 However, relaxing the significance threshold
to increase the number of instruments could increase the like-
lihood of weak instrument bias or horizontal pleiotropy. The
genetic instruments explained 187% of the phenotypic vari-
ability of the exposure variables. The minimum F statistic was
1213, consistent with the absence of weak instrument bias.
Moreover, analyses adopting a more stringent P-value for
instrument selection and the application of pleiotropy-robust
methods produced similar point estimates. The CAUSE analysis
comparing the causal with the shared model corroborates the
evidence of no association. The findings from our positive and
negative control analyses provided additional reassurance
against biasing pleiotropic pathways. A limitation is that MR
based on genetic summary statistics limits the range of analy-
ses that can be performed. However, based on the observed
and consistent negative results from several complementary
approaches with effect estimates close to one, it is unlikely
that the finding is distorted by any form of bias.
In conclusion, our study provides no evidence that AD has
a causal effect on depression, MDD or anxiety.
Data Availability Statement
All analyses were conducted using publicly available data. The
summary statistics for the atopic dermatitis genome-wide asso-
ciation study (GWAS) are available at https://data.bris.ac.uk/
data/dataset/28uchsdpmub118uex26ylacqm. The GWAS sum-
mary data for depression and major depressive disorder are
available at https://datashare.is.ed.ac.uk/handle/10283/3203,
and the GWAS summary data for anxiety are available at
http://www.med.unc.edu/pgc/download. The analysis code
in R is available on request.
Figure 1 Mendelian randomization estimates for the relationship between genetically instrumented atopic dermatitis (AD) and broad depression,
probable and International Classification of Diseases, Ninth/Tenth Revision (ICD-9/10)-based major depressive disorder (MDD), as well as
anxiety, using the inverse-variance (IV) weighted method. CI, confidence interval; OR, odds ratio.
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tionship between broad depression, probable and ICD-9/10-
based major depressive disorder, anxiety and atopic dermatitis.
Table S7 Mendelian randomization estimates for the rela-
tionship between atopic dermatitis and positive control out-
come asthma, as well as with negative control outcome type 2
diabetes.
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